Company Valuation: BriaCell Therapeutics Corp.

Data adjusted to current consolidation scope
Fiscal Period: July 2020 2021 2022 2023 2024 2025
Market Cap 1 5.148 78.61 101.5 106.4 13.63 12.81
Change - 1,427.04% 29.07% 4.9% -87.19% -6.05%
Enterprise Value (EV) 1 5.429 21.37 60.42 85.18 12.77 -5.058
Change - 293.6% 182.77% 40.98% -85.01% -139.6%
P/E - -54.3x -3.77x -5.12x -2.56x -0.12x
PBR - 1.37x 9.82x -28.2x -5.72x 0.77x
PEG - - -0x 0.2x 0x -0x
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA -1.13x -3.07x -3.96x -3.66x -0.38x 0.19x
EV / EBIT -1.12x -3.06x -3.95x -3.66x -0.38x 0.19x
EV / FCF 21x -3.65x -8.81x -5.37x -1.18x 0.27x
FCF Yield 4.77% -27.4% -11.3% -18.6% -84.8% 374%
Dividend per Share 3 - - - - - -
Rate of return - - - - - -
EPS 3 - -14.22 -259.8 -195 -43.68 -62.19
Distribution rate - - - - - -
Net sales - - - - - -
EBITDA 1 -4.821 -6.958 -15.27 -23.26 -33.25 -27.1
EBIT 1 -4.84 -6.973 -15.29 -23.27 -33.33 -27.2
Net income 1 -4.944 -0.4283 -26.84 -20.3 -4.791 -26.31
Net Debt 1 0.2808 -57.24 -41.04 -21.25 -0.8621 -17.87
Reference price 3 1,069.572 772.222 980.759 998.928 111.849 7.298
Nbr of stocks (in thousands) 4.81 102 103 107 122 1,755
Announcement Date 30/11/20 28/10/21 27/10/22 25/10/23 29/10/24 15/10/25
1USD in Million2CAD in Million3USD
Estimates


P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
20.59x7.25x14.66x1.42% 69.54B
36.89x9.62x29.41x0.04% 64.97B
30.69x6.58x17.2x-.--% 26.51B
-74.93x13.98x-67.43x-.--% 25.89B
-15.61x5.94x-7.46x-.--% 25.64B
58.27x21.67x43.95x0.26% 20.22B
27.27x5.11x16.98x-.--% 19.98B
1415.29x39.34x858.54x-.--% 15.69B
16.84x5x11.66x-.--% 13.49B
Average 168.37x 12.72x 101.95x 0.19% 31.33B
Weighted average by Cap. 93.83x 10.79x 57.82x 0.38%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA


  1. Stock Market
  2. Stocks
  3. BCT Stock
  4. BCTX Stock
  5. Valuation BriaCell Therapeutics Corp.